Dr. Angela Hirbe, M.D., Ph.D.
Claim this profileWashington University School of Medicine
Studies Soft Tissue Sarcoma
Studies Prostate Cancer
4 reported clinical trials
8 drugs studied
Area of expertise
1Soft Tissue Sarcoma
Stage IV
MTAP positive
Stage III
2Prostate Cancer
Affiliated Hospitals
Clinical Trials Angela Hirbe, M.D., Ph.D. is currently running
Circulating Tumor DNA
for Cancer
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Recruiting1 award N/A1 criteria
ADI-PEG 20 + Ifosfamide + Radiotherapy
for Soft Tissue Sarcoma
In this study, patients with soft tissue sarcoma (STS) will receive ADI-PEG 20 and ifosfamide in combination with radiation as neoadjuvant therapy. In phase I of the study, up to 5 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy.
Recruiting1 award Phase 1 & 2
More about Angela Hirbe, M.D., Ph.D.
Clinical Trial Related6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Angela Hirbe, M.D., Ph.D. has experience with
- Circulating Tumor DNA (ctDNA)
- Cabozantinib
- Ipilimumab
- Nivolumab
- ADI PEG20
- Ifosfamide
Breakdown of trials Angela Hirbe, M.D., Ph.D. has run
Soft Tissue Sarcoma
Prostate Cancer
Neck Cancer
Esophageal Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Angela Hirbe, M.D., Ph.D. specialize in?
Angela Hirbe, M.D., Ph.D. focuses on Soft Tissue Sarcoma and Prostate Cancer. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are MTAP positive.
Is Angela Hirbe, M.D., Ph.D. currently recruiting for clinical trials?
Yes, Angela Hirbe, M.D., Ph.D. is currently recruiting for 2 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Angela Hirbe, M.D., Ph.D. has studied deeply?
Yes, Angela Hirbe, M.D., Ph.D. has studied treatments such as Circulating Tumor DNA (ctDNA), Cabozantinib, Ipilimumab.
What is the best way to schedule an appointment with Angela Hirbe, M.D., Ph.D.?
Apply for one of the trials that Angela Hirbe, M.D., Ph.D. is conducting.
What is the office address of Angela Hirbe, M.D., Ph.D.?
The office of Angela Hirbe, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.